News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Macrocyclics Introduces New Offices In Asia And Europe


7/7/2014 9:07:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DALLAS, July 7, 2014/PRNewswire/ -- Macrocyclics, Inc. (an AREVA Med company) announced today the launch of new offices located in China, Japan, South Korea, and France. The production laboratory remains based in Dallas, Texas, USA; however, Asian and French customers will now have a local contact for placing orders and obtaining technical information about all products and services available from Macrocyclics, and the ability to communicate in their own language as well as English.

To reach Macrocyclics in their new offices, please use the following:

Beijing, China

Mrs. Carrie SONG

+86 150 1146 1640

china@macrocyclics.com

Tokyo, Japan

Mr. Sebastien PAES

+81 90 2620 5448

japan@macrocyclics.com

Seoul, South Korea

Mrs. Hye-Young PARK

+82 2 551 01 65

southkorea@macrocyclics.com

Limoges, France

Mr. Remy DUREAU

+33 6 46 42 45 65

france@macrocyclics.com

Macrocyclics specializes in the manufacture of customized chelating agents used in nuclear medicine and medical imaging. We also offer custom-made cGMP products for use in clinical trials, bioconjugation services, and consulting services that will help our customers select the proper isotopes for their particular needs.

Please visit http://www.macrocyclics.com for detailed information.

MORE ABOUT MACROCYCLICS

Macrocyclics is the global leader in high performance chelating agent technologies for medicine since 1995. Our team at Macrocyclics is dedicated to providing clients with both established and innovative chelating agents and services to meet the challenges of molecular imaging and nuclear medicine. www.macrocyclics.com

MORE ABOUT AREVA MED

AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 (212Pb), a rare metal that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: www.arevamed.com or www.targetedtrials.com. @AREVAmed

Macrocyclics
Garry Kiefer
T: +1 972 250 2248
F: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Tise
T: +1 301 841 1673
F: +1 240 235 0966
alison.tise@areva.com
@AREVAmed

SOURCE Macrocyclics, Help employers find you! Check out all the jobs and post your resume. Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES